Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have a consensus “Hold” rating on Aardvark Therapeutics, with five buys, four holds, two sells and one strong buy among 12 analysts. The average 12-month price target is $15.33.
• AARD opened at $5.79, down 12.5%, with a market capitalization of about $126.7 million; its 52-week range is $3.35 to $17.94.
• The company beat quarterly EPS expectations, reporting a loss of $0.66 versus the estimated $0.87 loss, but investor concerns remain over securities litigation and allegations involving disclosures about ARD-101’s safety, following a Phase 3 pause and FDA clinical hold.

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) have received a consensus recommendation of "Hold" from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $15.3333.

AARD has been the topic of several analyst reports. Weiss Ratings upgraded shares of Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 2nd. Morgan Stanley restated an "underweight" rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. Wall Street Zen upgraded Aardvark Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 15th. B. Riley Financial reduced their target price on Aardvark Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a report on Friday, May 15th. Finally, BTIG Research lowered Aardvark Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, May 15th.

Aardvark Therapeutics Stock Down 12.5%

AARD opened at $5.79 on Friday. The stock has a market capitalization of $126.69 million, a price-to-earnings ratio of -1.80 and a beta of 3.81. Aardvark Therapeutics has a twelve month low of $3.35 and a twelve month high of $17.94. The company has a 50-day simple moving average of $6.21 and a 200 day simple moving average of $6.02.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.21. Sell-side analysts anticipate that Aardvark Therapeutics will post -3.17 EPS for the current fiscal year.

Trending Headlines about Aardvark Therapeutics

Here are the key news stories impacting Aardvark Therapeutics this week:

• Neutral Sentiment: Several law firms are soliciting investors to seek lead-plaintiff status in a federal securities class action. The deadline is October 13, 2026, and the notices generally cover purchases made from February 13, 2025, through May 14, 2026, as well as shares bought in or traceable to the IPO. The announcements themselves do not represent new court findings or a company admission. Hagens Berman class action notice Bronstein Gewirtz and Grossman class action notice
• Negative Sentiment: The litigation alleges that Aardvark, its executives, and IPO-related disclosures made misleading or incomplete statements about the safety of the company’s ARD-101 therapy. According to the investor alert, the concerns preceded a pause in the Phase 3 program and a full FDA clinical hold. If sustained, the claims could increase legal costs, regulatory uncertainty, and reputational pressure while adding to concerns about ARD-101’s development prospects. SueWallSt AARD investor alert
• Negative Sentiment: The repeated notices from Rosen, Faruqi & Faruqi, Bragar Eagel & Squire, Frank R. Cruz, and other firms amplify visibility around the allegations and may weigh on sentiment, although they largely repeat the same underlying lawsuit rather than announce separate operational developments. Rosen AARD securities action notice

Institutional Trading of Aardvark Therapeutics

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Aardvark Therapeutics in the second quarter valued at about $42,000. Persistent Asset Partners Ltd bought a new position in shares of Aardvark Therapeutics in the fourth quarter worth about $56,000. New York State Common Retirement Fund bought a new position in shares of Aardvark Therapeutics in the second quarter worth about $99,000. MetLife Investment Management LLC acquired a new stake in shares of Aardvark Therapeutics in the 4th quarter valued at approximately $102,000. Finally, Bank of America Corp DE boosted its stake in shares of Aardvark Therapeutics by 72.9% in the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock valued at $108,000 after purchasing an additional 3,369 shares in the last quarter.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source